BHVN Valuation

Biohaven Ltd

Add to Watchlist

Advanced Chart

14.850

+0.53(3.701%)1D

Overview
Forecast
Valuation
Earnings

BHVN Relative Valuation

BHVN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BHVN is overvalued; if below, it's undervalued.

Historical Valuation

Biohaven Ltd (BHVN) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.44. The fair price of Biohaven Ltd (BHVN) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：14.85

Fair

-2.09

Trailing

Forward

-1.47

EV/EBITDA

Biohaven Ltd. (BHVN) has a current EV/EBITDA of -1.47. The 5-year average EV/EBITDA is -3.56. The thresholds are as follows: Strongly Undervalued below -9.30, Undervalued between -9.30 and -6.43, Fairly Valued between -0.70 and -6.43, Overvalued between -0.70 and 2.17, and Strongly Overvalued above 2.17. The current Forward EV/EBITDA of -1.47 falls within the Historic Trend Line -Fairly Valued range.

-1.34

EV/EBIT

Biohaven Ltd. (BHVN) has a current EV/EBIT of -1.34. The 5-year average EV/EBIT is -3.83. The thresholds are as follows: Strongly Undervalued below -7.43, Undervalued between -7.43 and -5.63, Fairly Valued between -2.03 and -5.63, Overvalued between -2.03 and -0.23, and Strongly Overvalued above -0.23. The current Forward EV/EBIT of -1.34 falls within the Overvalued range.

242.59

Biohaven Ltd. (BHVN) has a current PS of 242.59. The 5-year average PS is 70272.28. The thresholds are as follows: Strongly Undervalued below -398414.14, Undervalued between -398414.14 and -164070.93, Fairly Valued between 304615.49 and -164070.93, Overvalued between 304615.49 and 538958.70, and Strongly Overvalued above 538958.70. The current Forward PS of 242.59 falls within the Historic Trend Line -Fairly Valued range.

-1.88

P/OCF

Biohaven Ltd. (BHVN) has a current P/OCF of -1.88. The 5-year average P/OCF is -5.89. The thresholds are as follows: Strongly Undervalued below -10.39, Undervalued between -10.39 and -8.14, Fairly Valued between -3.63 and -8.14, Overvalued between -3.63 and -1.38, and Strongly Overvalued above -1.38. The current Forward P/OCF of -1.88 falls within the Overvalued range.

-2.23

P/FCF

Biohaven Ltd. (BHVN) has a current P/FCF of -2.23. The 5-year average P/FCF is -7.39. The thresholds are as follows: Strongly Undervalued below -17.46, Undervalued between -17.46 and -12.43, Fairly Valued between -2.36 and -12.43, Overvalued between -2.36 and 2.68, and Strongly Overvalued above 2.68. The current Forward P/FCF of -2.23 falls within the Overvalued range.

Biohaven Ltd (BHVN) has a current Price-to-Book (P/B) ratio of 11.67. Compared to its 3-year average P/B ratio of 7.81 , the current P/B ratio is approximately 49.41% higher. Relative to its 5-year average P/B ratio of 7.80, the current P/B ratio is about 49.61% higher. Biohaven Ltd (BHVN) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -20.98%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -20.98% , the current FCF yield is about -100.00% lower.

11.67

P/B

Median3y

7.81

Median5y

7.80

-42.67

FCF Yield

Median3y

-20.98

Median5y

-20.98

Competitors Valuation Multiple

The average P/S ratio for BHVN's competitors is 0.00, providing a benchmark for relative valuation. Biohaven Ltd Corp (BHVN) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Avadel Pharmaceuticals PLC

Viridian Therapeutics Inc

Amylyx Pharmaceuticals Inc

Loss

-100.00%

1.42B

Performance Decomposition

Market capitalization of BHVN increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of BHVN in the past 1 year is driven by Unknown.